

Review

Open Access

## Verification of the formulation and efficacy of *Danggui Buxue Tang* (a decoction of *Radix Astragali* and *Radix Angelicae Sinensis*): an exemplifying systematic approach to revealing the complexity of Chinese herbal medicine formulae

Qiutao Gao<sup>1</sup>, Jun Li<sup>1</sup>, Jerry Ka Hei Cheung<sup>1</sup>, Jinao Duan<sup>2</sup>, Anwei Ding<sup>2</sup>, Anna Wing Han Cheung<sup>1</sup>, Kuijun Zhao<sup>3</sup>, Winnie Zhuoming Li<sup>1</sup>, Tina Tingxia Dong<sup>1</sup> and Karl Wah Keung Tsim\*<sup>1</sup>

Address: <sup>1</sup>Department of Biology and the Center for Chinese Medicine, Hong Kong University of Science and Technology, Clear Water Bay Road, Hong Kong SAR, China, <sup>2</sup>Nanjing University of Traditional Chinese Medicine, 138 Xianlin Dadao, Xianlin University Town, Nanjing 210046, China and <sup>3</sup>Beijing Friendship Hospital (an affiliate of the Capital Medical University), 95 Yong'an Road, Beijing 100050, China

Email: Qiutao Gao - qiutaogao@gmail.com; Jun Li - lijun@UST.HK; Jerry Ka Hei Cheung - bojerry@ust.hk; Jinao Duan - duanja@163.com; Anwei Ding - awding@163.com; Anna Wing Han Cheung - boanna@ust.hk; Kuijun Zhao - zhao1959292@sina.com; Winnie Zhuoming Li - winnieli@ust.hk; Tina Tingxia Dong - botina@ust.hk; Karl Wah Keung Tsim\* - botsim@ust.hk

\* Corresponding author

Published: 29 November 2007

Received: 2 July 2007

*Chinese Medicine* 2007, 2:12 doi:10.1186/1749-8546-2-12

Accepted: 29 November 2007

This article is available from: <http://www.cmjournal.org/content/2/1/12>

© 2007 Gao et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

This article exemplifies a systematic approach to revealing the complexity of Chinese herbal medicine formulae through three levels of scientific research: standardization of herbs, verification of ancient formulae and mechanism studies. We use *Danggui Buxue Tang* (DBT) as an example for this approach. Among thousands of traditional Chinese medicine herbal formulae, almost all of which consist of multiple herbs, DBT is one of the simplest. Containing only two herbs, namely *Radix Astragali* (RA) and *Radix Angelicae Sinensis* (RAS), DBT is traditionally used to treat ailments in women. The weight ratio of RA to RAS in DBT was prescribed to be 5:1 as early as in 1247 AD. In addition to advanced chemical analysis of herbal constituents, DNA genotyping techniques have been developed for reliable standardization of RA and RAS. Chemical evaluation shows that main active constituents in DBT, including astragaloside IV, calycosin, formononetin and ferulic acid, were most abundant after extraction at the RA to RAS ratio of 5:1, whereas other tested RA to RAS ratios only gave sub-optimal levels of the active constituents. Biological evaluation indicates that bioactivities of DBT, e.g. immuno-modulatory, oestrotropic and estrogenic effects are also best exerted at the RA to RAS ratio of 5:1. Correlation analysis demonstrates statistically significant relationship between the tested chemical constituents and tested bioactivities. Up- and down-regulation of expression of some genes as potential biomarkers has been detected by using gene chip technology. This systematic approach on the basis of herbal standardization, chemical and biological verification and mechanism studies, as exemplified in this article, will be useful to reveal the complexity of not only DBT but also other Chinese medicine herbal formulae.

## Background

Traditional Chinese medicine (TCM) has been used to improve the well-being of the Chinese people for thousands of years. TCM products, many of which were raw materials, made up only 3% of the 16 billion USD international herbal medicine market in 2004 [1,2]. Since the market opening-up of China, international pharmaceutical companies have been gaining a market share in both conventional and herbal medicine products in China. In the 21<sup>st</sup> century, TCM products should meet stringent international quality and safety standards through modernization; otherwise they will lose their competitiveness.

Standardization as the basis of modernization and internationalization of TCM is the key to ensure the safety and efficacy of TCM products. At present, lack of standardization in TCM products impedes the development of TCM. For instance, it is common that different herbs have the same name or a single herb has different names in the market. Some herbs cultivated in different regions or harvested in different seasons may vary considerably in their chemical and biological properties. Most of the TCM products do not have specific biomarkers. TCM is traditionally administered in the form of a decoction with a combination of different herbs. The complexity of biological effects of the interactions among different compounds within a decoction complicates experimental studies to reveal the action mechanisms.

Among thousands of TCM formulae, *Danggui Buxue Tang* (DBT) is one of the simplest. The formula consists of only two herbs: *Radix Astragali* (RA, *Huangqi*) and *Radix Angelicae Sinensis* (RAS, *Danggui*) in a weight ratio of 5:1. According to a traditional method, the herbs are boiled together in two bowls of water at moderate heat until the final volume has been reduced to one bowl [2]. In a book entitled *Neiwaishang Bianhuo Lun* in 1247 AD, DBT was first described by Li Dongyuan, one of the four well-known TCM physicians during the Jin and Yuan Dynasties in China.

In this review, we summarize recent findings of DBT to exemplify a systematic approach to revealing the complexity of Chinese herbal medicine formulae through three levels of scientific research: standardization of raw materials, verification of ancient formulae and mechanism studies.


### Standardization of *Radix Astragali* and *Radix Angelicae Sinensis*

A reliably reproducible chemical composition of DBT is a prerequisite in delineating the biological effects of this Chinese medicine preparation. The quality of RA and RAS may be considerably influenced by weather, geographic location, soil conditions, and the methods of cultivation

and processing. Some Chinese medicinal materials with excellent quality are only produced in certain regions of China which are often referred to as 'the best growth region' or '*Didao*'. Therefore, how to authenticate and choose the best RA and RAS plays a critical role in ensuring the quality of DBT (Figure 1).

#### *Radix Astragali*

*Astragalus* L. (Leguminosae) is a large genus with over 2,000 species worldwide and more than 250 sections in angiosperm family *Fabaceae* (subfamily *Papilionoideae*). Both listed as the botanical sources of RA in Chinese Pharmacopoeia (2005) [3], *Astragalus membranaceus* (Fisch.) Bunge and *Astragalus membranaceus* (Fisch.) Bunge var. *mongholicus* (Bunge) P.K. Hsiao [4,5] are the most commonly used RA. The morphological appearances and chemical properties of RA and its adulterants show a remarkable resemblance [6-8]. The DNA sequences of 5S rRNA spacer, ITS and 18S rRNA coding region were determined and compared among ten *Astragalus* taxa [6-8]. With neighbor-joining and maximum parsimony analyses, phylogenetic trees were mapped according to their sequence diversity. *A. membranaceus* and *A. membranaceus* var. *mongholicus* have the highest sequence homology. The common substitute of RA in some parts of China is the roots of *Hedysarum polybotrys* which has very different



**Figure 1**  
**The authentic sources of RA and RAS. (a)** *A. membranaceus* and **(b)** *A. membranaceus* var. *mongholicus* are the sources for RA. **(c)** *H. polybotrys* is a common substitute for RA. **(d)** *A. sinensis* is the source for RAS. **(e)** *A. acutiloba* and **(f)** *A. gigas* are also sold as raw materials for RAS in the markets.


genetic makeup from that of the *Astragalus* species [9] (Figure 1).

HPLC and spectrophotometry were used to determine the levels of isoflavonoids, astragalosides, polysaccharides, amino acids and trace elements, which are the main active constituents in different *Astragalus* species and RA collected in different seasons and of various ages. The results

indicated that RA of three years of age from Shanxi, China (Figure 2a) contained the highest amounts of isoflavonoids, saponins and polysaccharides [6,10].

*Radix Angelicae Sinensis*

According to the Chinese Pharmacopoeia (2005) [3], RAS is the root of *Angelica sinensis* (Oliv.) Diels (family *Umbellaceae*); however, *Angelica acutiloba* (Sieb. et Zucc.) Kitag.



**Figure 2**

**Determination of the active constituents in RA and RAS.** (a) Amounts of total saponin, total isoflavonoid and total polysaccharides were determined in RA collected from various regions in China. (b) Amounts of ferulic acid and ligustilide were determined in RAS collected from various regions and countries. The roots of *A. sinensis* collected from Gansu, Yunnan, Sichuan and Shanxi, China were used. The roots of *A. acutiloba* from Hokkaido, Japan and *A. gigas* from Sokcho, Korea were used. Values are in g/100 g of dry herbal materials with means  $\pm$  SEM, n = 10. (c) RAS from Gansu, China and RA from Shanxi, China should be used for DBT preparation.

and *Angelica gigas* Nakai, mainly found in Japan and Korea respectively, are also sold as RAS in the markets of South East Asia [11-14] (Figure 1). Studies have shown that the three commonly used *Angelica* roots vary in their chemical composition, pharmacological properties and efficacy [9,11]. The 5S-rRNA spacer domains of the three species of *Angelica* were amplified and their nucleotide sequences were determined. The sequence of *A. sinensis* is 72.87% and 73.58% identical to those of *A. acutiloba* and *A. gigas* respectively, while *A. acutiloba* and *A. gigas* are 93.57% identical in their sequences [9]. The phylogenetic tree clearly reveals that the three *Angelica* species are divided into two clusters: *A. sinensis* is in one cluster and *A. acutiloba* and *A. gigas* are in another.

The main chemical constituents of *Angelica* roots are ferulic acid, Z-ligustilide, angelic acid, brefeldin A, butylenephthalide, butyphthalide, succinic acid, nicotinic acid, uracil and adenine [9,15-17]. The levels of ferulic acid and Z-ligustilide are often used as chemical markers for the quality control of *Angelica* roots [16]. In *A. sinensis* roots from Gansu, China, the levels of ferulic acid and Z-ligustilide are about ten-fold higher than those of the roots of *A. acutiloba* (from Japan) and *A. gigas* (from Korea) [9,17] (Figure 2b). Su Jing (659 AD) in *Tang Bencao* and Li Shizhen (1596 AD) in *Bencao Gangmu* recorded that *Angelica* roots of two years of age produced in Gansu were the authentic source. RAS from Gansu contains about two-fold higher amounts of Z-ligustilide and ferulic acid than those RAS from Yunnan, Shanxi or Sichuan, China [9] (Figure 2b). To ensure the best quality of DBT decoction, we suggest that standardized RA from Shanxi and standardized RAS from Gansu should be used in all DBT preparations (Figure 2c).

### Verification of the DBT formula

#### Chemical evaluation

Li Dongyuan (1247 AD) documented that RA and RAS combined at a ratio of 5:1 demonstrated the best efficacy. In a previous study [18], DBT was prepared by boiling the herbal mixture under various conditions and the results indicated that the 5:1 ratio indeed provided the maximum levels of active constituents of DBT. Furthermore, the levels of active constituents and biological activities of DBT extracts were investigated with preparations of RA and RAS at ratios of 1:1, 2:1, 3:1, 4:1, 5:1, 7:1 and 10:1.

Used as chemical markers, the main active constituents in DBT include RA-derived astragaloside IV, calycosin and formononetin, RAS-derived ferulic acid and ligustilide, and total saponins, total flavonoids and total polysaccharides [19]. The detected levels of the chemical markers varied significantly among the seven preparations (Figure 3). The level of astragaloside IV of the 5:1 ratio preparation was the highest, 2-fold higher than the 10:1 ratio prepara-


tion which recorded the lowest level [19]. The 5:1 ratio preparation also contained the highest level of calycosin, formononetin, and ferulic acid. As regards the levels of total saponins, total flavonoids and total polysaccharides, the 5:1 ratio DBT preparation recorded the highest levels (Figure 3) [19].

There are several possibilities for higher levels of active chemical constituents in DBT preparations. Firstly, compounds such as saponins (over 2% in total dry weight) [10,17] in RA may help increase the solubility of other compounds extracted from RAS. For example, astragaloside increases the solubility of RAS-derived ferulic acid and ligustilide. Secondly, ferulic acid and ligustilide are readily oxidized under heat, which means they can be degraded when boiled [9]. However, when RAS is boiled together with RA, compounds derived from RA may prevent this oxidization process, thereby producing a higher yield of ferulic acid and ligustilide in DBT preparations. Thirdly, the stability of those active constituents may be improved by having a cocktail of different chemicals. Further research is required for better understanding of this complexity.

#### Biological evaluation

According to TCM theories, DBT replenishes *qi* and nourishes *xue* (the blood). DBT is therefore used for treating menopausal symptoms [2]. Due to a deficiency of ovarian hormones, especially estrogen, women in menopause often suffer from hot flashes, sweating, anxiety, mood swings and an increased risk for other health problems, such as reduction of bone mineral density and cardiovascular diseases [20]. Apart from a lack of estrogen, the immune system is also involved in the menopausal symptoms. Steroid hormones may modulate the immune response [21] and immune reactions may also regulate the ovarian function [22]. Various bioactivities related to menopausal symptoms, such as osteotropic effect, estrogenic effect, anti-platelet aggregation effect and immunomodulatory effect have been used to evaluate the functional roles of DBT.

DBT extract was applied to a cultured human MG-63 osteosarcoma cell. Bone cell proliferation and differentiation were measured by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and alkaline phosphatase (ALP) assay. DBT induced both the proliferation and differentiation of osteoblast MG-63 cells in a dose-dependent manner. In both assays, DBT showed stronger effects than RA or RAS alone. In the MTT assay, the 5:1 ratio DBT extract stimulated MG-63 cell proliferation, which was 10–20% higher than the extracts of other ratios (Figure 4). For bone cell differentiation, the 5:1 ratio DBT preparation induced ALP activity to the highest



**Figure 3**

**Chemical constituents in RA, RAS and DBT.** (a) The amounts of astragaloside IV, calycosin, formononetin in DBT of various ratios of RA to RAS. (b) The amounts of Ligustilide, ferulic acid and total polysaccharides in DBT of various ratios of RA to RAS. Values are in mg/g of dry material (normalized by each herb weight) with means  $\pm$  SEM, n = 5, each with triplicate samples.

level among all ratios and showed the strongest osteotropic effect [19].


The estrogenic effects of DBT were tested by a cellular reporter system of transcriptional activation of estrogen receptor/promoter. A promoter/reporter construct (pERE-Luc) corresponding to the responsive elements of estrogen receptor was stably transfected into MCF-7 cells. The DBT extracts of various ratios were applied onto the cultures for 2 days. Two parameters, namely cell number and promoter activity (luciferase activity), were determined. While DBT was not able to alter the proliferation of MCF-7 cells, the estrogen-driven promoter activity was markedly induced by DBT (Figure 4); the 5:1 ratio DBT showed the strongest effect in inducing the promoter activity than RA, RAS alone or the extracts of other ratios [19].

In anti-platelet aggregation assay, the activity of DBT in preventing ADP-induced platelet aggregation was determined. The ratios 5:1 and 7:1 DBT extracts demonstrated higher levels of activity in preventing platelet aggregation than either RA, RAS alone or the extracts of other ratios (Figure 4) [19].

In a study of immuno-modulatory effects, DBT preparations of various ratios were applied to cultured T-lymphocytes and macrophages. In cultured T-lymphocytes, DBT induced markedly cell proliferation, interleukin-2 secretion and the phosphorylation of extracellular signal-regulated kinase (ERK1/2). In addition, the phagocytosis of cultured macrophages was elevated by DBT treatment. The immuno-modulatory effects of 5:1 ratio DBT were the strongest [23] (Table 1).

In addition to the *in vitro* assays, the 5:1 ratio of RA and RAS in DBT was further tested and verified by animal studies. In DBT-administrated mice, the 5:1 ratio preparation was the most effective decoction in triggering immune responses [24,25].

The pharmacological studies in animals also suggest that DBT has the ability to promote hematopoiesis, to stimulate blood circulation, to prevent osteoporosis and to counter oxidative stress [19,26,27]. Moreover, DBT is known to enhance myocardial mitochondria and glutathione status in red blood cells, thereby increasing their resistance to injury induced by oxidative stress [28]. In



**Figure 4**  
**Biological activities of RA, RAS and DBT of various RA to RAS ratios.** RA, RAS and DBT of various RA to RAS ratios were tested for MG-63 cell proliferation (MTT assay), MG-63 cell differentiation (ALP assay), estrogenic response (estrogen promoter) and anti-platelet aggregation activity. The values are means ± SD, n = 5, each with triplicate samples.

rats, *DBT* protected against myocardial ischemia-reperfusion injury in a dose-dependent manner [28]. A more potent cardio-protection was demonstrated in *DBT*-treated rats than in rats treated with either extracts of *RA*, *RAS* alone, or a mixture of *RA* and *RAS* (not boiled together). When the mice were administered orally with *DBT*, the serum collected from abdominal aorta was added to an *in vitro* cultivating system of mouse hematopoietic progenitor cells. The decoction-contained serum showed promoting actions to CFU-GM and CFU-E. Once again, the action of the 5:1 ratio *DBT* was 97.81% stronger than that of the 1:1 ratio extract [29,30] (Table 2).

**Mechanism studies**

*Correlation between chemical fingerprints and bioactivities of DBT*  
 Fifty-four chemical peaks were detected in *DBT* extracts by an HPLC analysis (Figure 5a) and a total of over 100 *DBT* extracts from various preparations were analyzed [27]. Among these 54 peaks, the markers for *RA*-derived astragaloside IV, calycosin and formononetin, and for *RAS*-derived ferulic acid and ligustilide were identified. In analysis of correlation, the identified 54 peak areas together with the contents of total saponins, total flavonoids and total polysaccharides were considered as independent variables. The results of the four bioactivities, namely proliferation and differentiation of MG-63 cells, estrogenic property in MCF-7 cells and anti-platelet aggregation activity, were considered as dependent variables. By analyzing the correlation of these two kinds of variables, coefficients of correlation between the HPLC data of the 57 chemicals and the bioassay data of the *DBT* extracts were obtained. The values of the coefficients indicate possible relationship of these chemical peaks with bioactivities, where positive values suggest positive effects of chemicals

**Table 1: Biological evaluation of DBT (in vitro studies)**

Findings	Model	Treatment	Reference
The 5:1 ratio <i>DBT</i> showed stronger effects in stimulating MG-63 cell proliferation and induced ALP activity to the highest level among all groups.	Cultured human MG-63 osteosarcoma cells	<i>DBT</i> of various ratios of <i>RA</i> and <i>RAS</i> , compared with β-estradiol and negative control	Dong et al. [19]
The 5:1 ratio <i>DBT</i> showed the strongest effect in inducing the estrogen-driven promoter activity than <i>RA</i> , <i>RAS</i> alone or the extracts of other ratios.	Cultured MCF-7 cells	<i>DBT</i> of various ratios of <i>RA</i> and <i>RAS</i> , compared with β-estradiol and negative control	Dong et al. [19]
The ratios 5:1 and 7:1 <i>DBT</i> showed higher levels of activity in preventing platelet aggregation.	ADP induced-platelet aggregation in blood from adult New Zealand white rabbits	<i>DBT</i> of various ratios of <i>RA</i> and <i>RAS</i> , compared with ticlopidine and negative control	Dong et al. [19]
<i>DBT</i> induced cell proliferation, interleukin-2 secretion and the phosphorylation of extracellular signal-regulated kinase (ERK1/2) in cultured T-lymphocytes. The 5:1 ratio <i>DBT</i> showed the strongest immuno-modulatory effects.	Cultured T-lymphocytes and macrophages	<i>DBT</i> of various ratios of <i>RA</i> and <i>RAS</i> , compared with PHA, PMA, Zymosan A and negative control	Gao et al. [23]

**Table 2: Biological evaluation of DBT (in vivo studies)**

Findings	Model	Treatment	Reference
DBT had significantly higher RBC and Hb levels in both normal and anemic mice than those in RA, RAS and control.	Kunming mice, male, RBC, Hb	Normal mice in 4 groups: RA, RAS, DBT and control; Anemic mice in 4 groups: RA, RAS, DBT and control	Wu BC et al. [24]
DBT was the most effective decoction in triggering immune responses.	Kunming mice, RBC, Hb, WBC, Plt, reticulocyte, nucleated cells of bone cavity, weight of pancreas and thymus	Mice in 5 groups: RA, RAS, DBT, RA+RAS (1:1) and control	Li YK et al. [25]
DBT alleviated cardiac injury in ischemia reperfusion.	Wister rats (male), amplitudes of LVSP and $\pm dp/dt_{max}$ , arterial pressure, Na <sup>+</sup> -K <sup>+</sup> -ATP activity, level of MDA production, cAMP content	Rats in myocardial ischemia reperfusion injury; i.v.	Wu DZ et al. [26]
DBT increased the levels of RBC, WBC, and BMNC. Some DBT promoted the proliferation of BMNC and increased the level of CFU-Mix.	Kunming mice, ICR mice, Balb/c mice, RBC, WBC, reticulocytes and BMNC	Mice in 4 groups: normal, model, DBT without polysaccharides, DBT with polysaccharides	Ning L et al. [27]
DBT enhanced myocardial mitochondria and red blood cell glutathione status.	Rats, myocardial mitochondrial status, RBC glutathione status	Rats in 5 groups: RA, RAS, DBT, RA + RAS (not boiled together) and control; orally administered	Mak DH et al. [28]
DBT inhibited growth of GM-CFU, while the decoction-containing serum promoted growth of GM-CFU.	Kunming mice, GM-CFU	DBT was administered orally; serum collected from abdominal aorta was added to an <i>in vitro</i> cultivating system of mouse hematopoietic progenitor cells.	Zhang YH et al. [29]
The decoction-containing serum showed promoting actions to CFU-E. RA+RAS (5:1) was 97.81% stronger than RA+RAS (1:1).	Kunming mice, CFU-E	DBT was administered orally; serum collected from abdominal aorta was added to an <i>in vitro</i> cultivating system of mouse hematopoietic progenitor cells.	Zhang YH et al. [30]

on bioactivities and negative values suggest negative effects.

In the assay of MG-63 cell proliferation, astragaloside IV, formononetin, total saponins and total flavonoids are correlated with the bioactivities (Figure 5b). In the assay of MG-63 cell differentiation, formononetin, total saponins and total flavonoids are correlated with the bioactivities. In the analysis of estrogen promoter in MCF-7 cells, ferulic acid are correlated with the bioactivities. Calycosin and total polysaccharides were two very important factors in the assay of anti-platelet aggregation. On the other hand, the amount of ligustilide showed negative effects in all bioassays (Figure 5b). Other components of DBT, such as those corresponding to peaks 5 to 15, have high correlation coefficients with the bioactivities, but are yet to be identified.

*Specific estrogenic and immuno-modulatory effects of DBT*

The estrogenic effects of DBT were investigated by determining the levels of phosphorylation of estrogen receptor  $\alpha$  (ER $\alpha$ ) and extracellular signal-regulated kinase 1/2 (ERK1/2) in cultured MCF-7 cells. In contrast to estrogen, DBT triggered the phosphorylation of ER $\alpha$  and ERK1/2 at both S118 and S167 in a time-dependent manner. Although the activity of the estrogen-responsive element in pERE-Luc stably expressing MCF-7 cells was activated by extracts of either RA or RAS alone, or by a mixture of


RA and RAS, the phosphorylation of ER $\alpha$  at S167 and of ERK1/2 were only found in DBT-treated cultures. Interestingly, the specific estrogenic effects of DBT were not only shown in the MCF-7 cells [31].

In cultured T-lymphocytes, the phosphorylation of the ERK 1 (about 42 kDa) and ERK 2 (about 44 kDa) was increased by DBT [30]. The induction was transient. An approximately eight-fold increase of ERK phosphorylation was detected 20 minutes after DBT was applied, whereas the phosphorylation was undetectable in the cultures treated with extracts of either RA or RAS alone [31]. Moreover, the phosphorylation of ERK in T-lymphocytes could not be activated by a simple mixture of extracts of RA and RAS. This result suggests that boiling RA and RAS together is essential for DBT to exert estrogenic effects.


*Genomics*

For decades, scientists mainly isolated pure chemicals from herbal extracts and then screened for biological activities and possible targets. This strategy does not guarantee to isolate and/or identify active chemicals from well-known medicinal plants because a single chemical compound may not fully account for the overall effects of herbal extracts. Recent advances in genomics and proteomics have enriched our tool sets to reveal the complex nature of TCM decoctions. An experiment on DBT-regulated genes was carried out in our laboratory using gene

(a)



(b)



**Figure 5**

**Correlation coefficients between the data of 57 chemicals and the four bioassays. (a)** Fifty-four peaks in typical HPLC fingerprints of *DBT*. In the HPLC fingerprint of 203 nm, astragaloside IV and other 16 peaks had a retention time between 70 to 120 min. In the HPLC fingerprint of 254 nm, ferulic acid, calycosin, formononetin, ligustilide and other 32 peaks had a retention time between 0 to 70 min. The 54 peaks are numbered, where astragaloside IV (1), ferulic acid (19), calycosin (33), formononetin (50) and ligustilide (53) are identified and served as standards. **(b)** The correlation coefficients between the data of 57 chemicals with the four bioassays. The correlation coefficient is in Y-axis and the peak number is in X-axis. Individual chemical markers are indicated by arrowheads and denoted by astragaloside IV (A), ferulic acid (B), calycosin (C), formononetin (D), ligustilide (E), total saponins (F), total flavonoids (G) and total polysaccharides (H). All correlations were tested to be statistically significant ( $P < 0.05$ ).



**Table 3: Genes regulated by DBT, RA and RAS in cultured MG-63 cells**

Genes	Number of genes *
Total	8064
Control	606
DBT-activated	883
DBT-specific	403
RA-activated	660
RA-specific	172
RAS-activated	1062
RAS-specific	473

\*Significant changes of gene expression are defined as regulation, which can be either up-regulation when fluorescent signal in the sample was 200% greater than that of control, or down-regulation when the signal was 50% less than that of control.

chip (i.e. microarray) technology. Cultured MG-63 cells were treated with 1 mg/ml of RA, RAS or DBT for 24 hours. The isolated mRNAs were analyzed using microarray, which is a quantitative method to investigate the change of mRNA expression profiles between the control and treatment groups. A total of 8064 genes were screened. Significant changes in gene expression were found after the treatment of DBT, RA or RAS (Table 3). A total of 883 genes were either up or down regulated by DBT treatment of which 403 genes were DBT-specific; 660 genes were regulated by RA treatment of which 172 genes were RA-specific; 1,062 genes were regulated by RAS treatment of which 473 genes were RAS-specific. In addition, 279 genes were commonly regulated by the extracts of DBT, RA or RAS. The genomic analysis demonstrated not only the activation effect of DBT in stimulating the proliferation and differentiation of the cultured osteoblasts but also a set of candidates of biomarkers that are specifically activated by DBT. These DBT-specific changes in gene expression may be useful in developing biomarkers for quality control of DBT. After identification of these DBT-specific genes and their roles, it will be easier to elucidate the action mechanism of DBT.

## Conclusion

In verification studies of DBT decoction, the quality of herbal materials is ensured by authentication analysis. The ancient formula of RA to RAS ratio at 5:1 has been confirmed in both chemical composition and biological responses both *in vivo* and *in vitro*. Mechanism studies have also revealed some therapeutic effects of DBT. It is hoped that a systematic research and development approach, as exemplified in this article, will provide an effective method to develop Chinese herbal medicine products.

## Competing interests

The author(s) declare that they have no competing interests.

## Authors' contributions

QG and JL drafted the manuscript and did most of the experiments described in this review. JC, AC, KZ and WL assisted in the experiments. JD, AD, TD and KT helped draft and revise the manuscript. KT supervised this work. All authors read and approved the final manuscript.

## Acknowledgements

The research was supported by grants to KT from the University Grants Committee (AoE/B-10/01) and Research Grants Council (HKUST6419/06M) of the Hong Kong SAR, Jiangsu Key Laboratory for TCM Formulae Research (LTCMF) and Nanjing University of Chinese Medicine (FJK 200601 I). In 2005, KT did the research as a visiting professor at the School of Pharmaceutical Sciences, Peking University.

## References

1. Tsim KWK, Kung SD: **Modernization of traditional Chinese medicine: problems in safety and quality assurance.** In *Vision of 2050: Agriculture in China* Edited by: Tso, Ho. Beijing: Chinese Agricultural University Press; 2004:361-373.
2. Tsim KWK: **Danggui Buxue Tang (DBT, Chinese Angelica Decoction): a sample trial in TCM standardization.** *Asia-Pacific Biotech News (APBN)* 2005, **8**:1316-1321.
3. Zheng XY: *Pharmacopoeia of the People's Republic of China.* Beijing Beijing: Chemistry Industry Press; 2005.
4. Sinclair S: **Chinese herbs: a clinical review of Astragalus, Ligusticum and Schizandrae.** *Altern Med Rev* 1998, **3**:338-344.
5. Hsiao PG: **Studies on the original plant and pharmacognosy of traditional Chinese medicine: Huangqi.** *Acta Pharm Sin* 1964, **11**:117-123.
6. Ma XQ, Duan JA, Zhu DY, Dong TTX, Tsim KWK: **Chemical comparison of Astragali Radix (Huangqi) from different regions of China.** *Nat Med* 2000, **54**:213-218.
7. Ma XQ, Duan JA, Zhu DY, Dong TTX, Tsim KWK: **Species identification of Radix Astragali (Huangqi) by DNA sequence of its 5S-rRNA spacer domain.** *Phytochemistry* 2000, **54**:363-368.
8. Dong TTX, Ma XQ, Clarke C, Song ZH, Ji ZN, Lo CK, Tsim KWK: **Phylogeny of Astragalus in China: Molecular evidence from the DNA sequences of 5S rRNA spacer, ITS, and 18S rRNA.** *J Agric Food Chem* 2003, **51**:6709-6714.
9. Zhao KJ, Dong TTX, Tu PF, Song ZH, Lo CK, Tsim KWK: **Molecular genetic and chemical assessment of Radix Angelica (Danggui) in China.** *J Agric Food Chem* 2003, **51**:2576-2583.
10. Ma XQ, Shi Q, Duan JA, Dong TTX, Tsim KWK: **Chemical analysis of Radix Astragali (Huangqi) in China: A comparison with its adulterants and seasonal variations.** *J Agric Food Chem* 2002, **50**:4861-4866.
11. Hu SL: *The Authentic and Superior Medicinal Herbs in China* Harbin: Heilongjiang Publishing House of Science and Technology; 1989:461-463.
12. Zhu YC: *Plant Medicinal of Northeast China* Harbin: Heilongjiang Publishing House of Science and Technology; 1989:808.
13. Zheng HZ, Dong ZH, She J: *Modern Study of Traditional Chinese Medicine Volume Two.* Beijing: Xueyuan Press; 1997:1810.
14. Watanabe A, Araki S, Kobari S, Udo H, Tsuchida T, Uno T, Kosaka N, Shimomura K, Yamazaki M, Saito K: **In vitro propagation, restriction fragment length polymorphism, and random amplified polymorphic DNA analysis of Angelica plants.** *Plant Cell Rep* 1998, **18**:187-192.
15. Song ZY: *The Modern Studies on the Chinese Meteria Medica Volume 2.* Beijing: Peking Union Medical College & Beijing Medical University Press; 1996:1-25.
16. Wagner H, Bauer R, Xiao PG, Chen JM, Michler H: *Chinese Drug Monographs and Analysis: Angelica sinensis* Wald Verlag, Germany; 2001.
17. Lao SC, Li SP, Kan KKW, Li P, Wan JB, Wang YT, Dong TTX, Tsim KWK: **Identification and quantification of 13 components in Angelica sinensis (Danggui) by gas chromatography-mass spectrometry coupled with pressurized liquid extraction.** *Anal Chim Acta* 2004, **526**:131-137.
18. Song ZH, Ji ZN, Lo CK, Dong TT, Zhao KJ, Li OT, Haines CJ, Kung SD, Tsim KWK: **Chemical and biological assessment of a tra-**

- ditional Chinese herbal decoction prepared from *Radix Astragali* and *Radix Angelicae Sinensis*: orthogonal array design to optimize the extraction of chemical constituents. *Planta Med* 2004, **70**:1222-1227.
19. Dong TTX, Zhao KJ, Gao QT, Ji ZN, Zhu TT, Li J, Duan R, Cheung AW, Tsim KWK: **Chemical and biological assessment of a Chinese herbal decoction containing *Radix Astragali* and *Radix Angelicae Sinensis*: Determination of drug ratio in having optimized properties.** *J Agric Food Chem* 2006, **54**:2767-2774.
  20. Harlow BL, Signorello LB: **Factors associated with early menopause.** *Maturitas* 2000, **35**:3-9.
  21. Manyonda IT, Pereira RS, Makinde V, Brincat M, Varma RT: **Effect of 17 beta-oestradiol on lymphocyte subpopulations, delayed cutaneous hypersensitivity responses and mixed lymphocyte reactions in post-menopausal women.** *Maturitas* 1992, **14**:201-210.
  22. Bukovsky A, Presl J: **Control of ovarian function by the immune system: commentary on the criticisms of Schenzle.** *Med Hypotheses* 1981, **7**:1-14.
  23. Gao QT, Cheung JK, Li J, Chu GK, Duan R, Cheung AW, Zhao KJ, Dong TTX, Tsim KWK: **A Chinese herbal decoction, *Danggui Buxue Tang*, prepared from *Radix Astragali* and *Radix Angelicae Sinensis* stimulates the immune responses.** *Planta Med* 2006, **72**:1227-1231.
  24. Wu BC, Sun XF, Yang GY: **Studies on different combination of the *Dang Gui Buxue* decoction.** *Chin Med Mater Heilongjiang* 1989, **4**:41-45.
  25. Li YK, Xu J, Zhang XC: **Pharmacology study on *Danggui Buxue* decoction.** *Chin J Herbal Pharmacol Ther* 1992, **8**:16-20.
  26. Wu DZ, Song CQ, Hen ZF, Kong JL, Fan Y, Hu ZB: **Effects of *Angelica sinensis* decoction for supplementing blood on the cardiac function in myocardial ischemia reperfusion injury of rats.** *Pharmacol Clin Chin Mater Med* 1999, **15**:3-6.
  27. Ning L, Chen CX, Jin RM, Wu YP, Zhang HG, Sun CL, Song CQ, Hu ZB: **Effect of components of *Danggui Buxue* decoction on hematopenia.** *Chin J Chin Mater Med* 2002, **27**:50-52.
  28. Mak DH, Chiu PY, Dong TTX, Tsim KWK, Ko KM: ***Danggui Buxue Tang* produces a more potent cardioprotective effect than its component herb extracts and enhances glutathione status in rat heart mitochondria and erythrocytes.** *Phytother Res* 2006, **20(7)**:561-567.
  29. Zhang YH, Wu GL, Jiang TL: **Effects of *Danggui Buxue* Decoction and the decoction-contained Serum on granulocyte-macrophage progenitor cell colony forming unit (GM -CFU).** *Chin J Exp Tradit Med Formulae* 1999, **5**:30-32.
  30. Zhang YH, Wu GL, Jiang TL: **Effect of *Danggui Buxue* Decoction and the decoction-contained serum on erythroid progenitor cell colony forming unit (CFU-E) in mice.** *Chin J Exp Tradit Med Formulae* 1999, **5**:33-36.
  31. Gao QT, Choi RC, Cheung AW, Zhu JT, Li J, Chu GK, Duan R, Cheung JK, Jiang ZY, Dong XB, Zhao KJ, Dong TT, Tsim KWK: ***Danggui Buxue Tang* – a Chinese herbal decoction activates the phosphorylations of extracellular signal-regulated kinase and estrogen receptor alpha in cultured MCF-7 cells.** *FEBS Lett* 2007, **581**:233-240.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

